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Metabolic Encephalopathy and Lipid
Storage Myopathy Associated with a
Presumptive Mitochondrial Fatty Acid
Oxidation Defect in a Dog
Vanessa R. Biegen1*, John P. McCue1, Taryn A. Donovan1 and G. Diane Shelton2
1 The Animal Medical Center, New York, NY, USA, 2 The Department of Pathology, School of Medicine, University of California
San Diego, La Jolla, CA, USA
A 1-year-old spayed female Shih Tzu presented for episodic abnormalities of posture and
mentation. Neurological examination was consistent with a bilaterally symmetric multifocal
encephalopathy. The dog had a waxing-and-waning hyperlactemia and hypoglycemia.
Magnetic resonance imaging revealed bilaterally symmetric cavitated lesions of the
caudate nuclei with less severe abnormalities in the cerebellar nuclei. Empirical therapy
was unsuccessful, and the patient was euthanized. Post-mortem histopathology revealed
bilaterally symmetric necrotic lesions of the caudate and cerebellar nuclei and multi-organ
lipid accumulation, including a lipid storage myopathy. Malonic aciduria and ketonuria
were found on urinary organic acid screen. Plasma acylcarnitine analysis suggested a
fatty acid oxidation defect. Fatty acid oxidation disorders are inborn errors of metabolism
documented in humans, but poorly described in dogs. Although neurological signs have
been described in humans with this group of diseases, descriptions of advanced imaging,
and histopathology are severely lacking. This report suggests that abnormalities of fatty
acid metabolism may cause severe, bilateral gray matter necrosis, and lipid accumulation
in multiple organs including the skeletal muscles, liver, and kidneys. Veterinarians should
be aware that fatty acid oxidation disorders, although potentially fatal, may be treatable.
A timely definitive diagnosis is essential in guiding therapy.
Keywords: metabolic encephalopathy, lipid storage myopathy, inborn error of metabolism, fatty acid oxidation,
magnetic resonance imaging
CASE PRESENTATION
A 1-year-old spayed female Shih Tzu was evaluated at The Animal Medical Center for several
episodes of dull mentation, disorientation, and difficulty walking. At 4months of age, the dog
presented to another hospital for acute hypertonic non-ambulatory tetraparesis, which improved
quickly to a non-ambulatory paraparesis, and diffuse generalized tremors. Neurological abnormali-
ties included proprioceptive deficits in all limbs and a positional vertical nystagmus. Complete blood
count, serum chemistry panel, pre- and postprandial bile acids, abdominal ultrasound, thoracic
Abbreviations: CPT, carnitine palmitoyltransferase; FAOD, fatty acid oxidation defect/disorder; LCFA, long-chain fatty acids;
MADD, multiple acyl-CoA dehydrogenase deficiency; MCADD, medium-chain acyl-CoA dehydrogenase deficiency; MCD,
malonyl-CoAdecarboxylase;MCFA,medium-chain fatty acids; OA, organic aciduria; SCFA, short-chain fatty acids; VLCADD,
very long-chain acyl-CoA dehydrogenase deficiency; VLCFA, very long-chain fatty acids.
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and abdominal radiographs, and a panel screening for tick-borne
diseases utilizing polymerase chain reaction1 failed to identify any
significant abnormalities. The dog was treated supportively with
intravenous fluids and released the following day when clinical
signs resolved. The dog had three additional episodes over the
following 8months, all with spontaneous improvement within
hours. All episodes were associated with perceived stressors, such
as holidays and the presence of visitors in the house. The dog
was reportedly normal between episodes. Two days prior to pre-
sentation, the dog was found in dorsal recumbency with pelvic
limb extensor rigidity and an abnormal mentation. Resolution
occurred within hours. The following 2 days, the dog hadmultiple
episodes of heavy panting and abnormal mentation lasting several
hours, followed by an acute onset of non-ambulatory tetraparesis
and disorientation just prior to presentation.
On presentation, the dog had a rectal temperature of 103.1°F
and a systolic blood pressure of 220mmHg, both of which
returned to normal within hours following initial stabilization
and therapy with hypertonic saline and replacement crystal-
loid intravenous fluids. Physical examination was otherwise nor-
mal. Abnormalities on neurological examination included a dull
mentation, fine intermittent head tremors, non-ambulatory tetra-
paresis with absent postural reactions in all limbs, absent men-
ace responses bilaterally, and a bilateral positional ventrolateral
strabismus. Muscle tone and spinal reflexes were normal. These
findings were consistent with a bilaterally symmetric multifocal
encephalopathy with differential diagnoses including congenital
(e.g., hydrocephalus), toxic (e.g., lead), metabolic (e.g., hepatic
encephalopathy, inborn error of metabolism), neurodegenerative
(e.g., idiopathic superficial neocortical degeneration and atro-
phy of young dogs), nutritional (e.g., thiamine deficiency), and
viral etiologies. Metabolic encephalitides were prioritized due to
the episodic nature of the signs. A venous blood gas and elec-
trolyte panel revealed a mild hyperlactemia (2.63mmol/L; refer-
ence interval, 0.5–2.5mmol/L) andmild hypocapnia (32.9mmHg;
reference interval 35–45mmHg); pH was 7.4 (reference interval,
7.35–7.45) and bicarbonate was 19.9mmol/L (reference inter-
val, 18–24mmol/L). The dog was treated with a bolus of 3%
hypertonic saline (5.3mL/kg IV), maropitant citrate (1mg/kg IV
q 24 h), pantoprazole (1mg/kg IV q 24 h), and a replacement
crystalloid2 (4mL/kg/h) supplemented with potassium chloride
(20meq/L). After an overnight fast, the patient had a worsened
mentation and a serum lactate of 13.2mmol/L. The dog became
hypertensive with a blood pressure of 186/112mmHg and devel-
oped a sinus tachycardia of 175 bpm. Boluses of the replacement
crystalloid (see text footnote 2) (22mL/kg IV) and 3% hypertonic
saline (5.3mL/kg IV) were administered. Lactate was noted to
improve 5.77mmol/L following these interventions, and the dog’s
mentation transiently improved.
A resting ammonia was normal (5mol/L; reference inter-
val, 2–75mol/L). Complete blood count and serum chem-
istry profile were recommended but declined by the owner.
Cervical and brain MRI performed with a 1.5-T unit3 revealed
non-contrast-enhancing bilaterally symmetric, teardrop-shaped
1Fastpanel PCR Canine Tick Bourne Panel, Antech Diagnostics, Irvine, CA, USA.
2Plasmalyte A, Abbott Animal Health, Abbott Park, IL, USA.
3Philips Achieva 1.5-T MRI, Philips Healthcare, Andover, MA, USA.
T2-hyperintensities of the caudate nuclei that were hypointense
with hyperintense periphery on FLAIR and hypointense to gray
matter on T1-weighted images (Figures 1A,B). Non-contrast
enhancing, bilaterally symmetric, subtle T2-hyperintensities of
the cerebellar nuclei that remained hyperintense on FLAIR and
isointense to gray matter on T1-weighted images were also
identified (Figure 2A). Cerebrospinal fluid collected from the
atlanto-occipital subarachnoid space had a normal nucleated cell
count (1/L; reference interval, <4/L) and protein concentra-
tion (11mg/dL; reference interval,<35mg/dL); cytological exam-
ination disclosed primarily mature lymphocytes with occasional
large monocytoid mononuclear cells. CSF lactate was also nor-
mal (1.2mmol/L; reference interval, 0.416–1.850mM/L) and was
similar to that of a control dog measured the same day (1).
Based on the episodic, multifocal, and symmetrical clinical
signs and the bilaterally symmetric gray matter lesions on MRI,
etiological categories including toxic, metabolic, degenerative,
and nutritional abnormalities were considered. The dog had no
history of toxin exposure and was on a balanced commercial
canine diet. A quantitative urine organic acid screen was submit-
ted to Biochemical Genetics Laboratory at the University of Cali-
fornia San Diego during a period of normoglycemia, the results of
which were not available for several weeks. Intravenous replace-
ment crystalloids (see text footnote 2) were continued with the
addition of B-complex vitamins (2mL/L of replacement crystal-
loid). Thiamine therapy was also instituted (11mg/kg SQ q 12 h).
Over the following 3 days, there was no improvement in neu-
rological status. The dog became intermittently hypoglycemic
(as low as 50mg/dL; reference interval, 62–114mg/dL), which
was responsive to feedings. Blood lactate varied between 1.05
and 4.62mmol/L, often accompanied by panting and resultant
hypocapnia, and when>2mmol/L, was treated with fluid boluses
in addition to maintenance fluids. On day 3, methylprednisolone
sodium succinate (30mg/kg IV) was administered and oral pred-
nisone (0.54mg/kg PO q 12 h) was initiated due to concerns
regarding possible inflammation associated with the areas repre-
sented by hyperintense rings on FLAIR sequences. Levetiracetam
(27mg/kg PO q 8 h) was also initiated for its reported neuro-
protective qualities (2). The patient was humanely euthanized
on day 4 due to lack of improvement. Consent was obtained for
post-mortem examination.
On post-mortem examination, gross abnormalities included
bilateral cavitated foci within the caudate nuclei (Figure 1C), pal-
lor of several focal skeletal muscle bundles, dorsal and pelvic limb
muscle wasting,multifocal to coalescing hepatic parenchymal pal-
lor, and congestion of multiple organs. Histopathological exami-
nation of the brain identified severe, bilateral focal necrosis of the
caudate nuclei with cavitation, Gitter cell infiltration, rare axonal
swelling (spheroids), regional rarefaction and gliosis (Figure 1D).
In the cerebellum, neuropil vacuolation was present at the level
of the lateral, interposital, and fastigial nuclei, accompanied by
gliosis, glial cytoplasmic swelling, and axonal spheroid forma-
tion (Figures 2B,C). There was also regional granular cell layer
depletion within the cerebellar cortex. Within the brainstem, mild
vacuolation was found bilaterally in the region of the vestibular
and cuneate nuclei. In all segments of the spinal cord, there was
mild, multifocal myelin vacuolation withmyelinophages andmild
multifocal gray matter gliosis. Histologically examined skeletal
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FIGURE 1 | (A) Transverse T2-weighted turbo spin echo MR image of a 1-year-old spayed female Shih Tzu presenting for episodic multifocal encephalopathy. There
are bilaterally symmetric, teardrop-shaped hyperintensities of the caudate nuclei suggestive of a metabolic encephalopathy. (B) Transverse FLAIR MR image at the
same level as in (A) reveals the caudate nuclear lesions are hypointense with hyperintense rims. This suggests a low-protein cavitated lesion within the caudate nuclei
surrounded by either edema, proteinaceous fluid, inflammation, or, less likely, neoplastic tissue. (C) Formalin fixed brain, dog. Photograph of a transverse section of
the cerebrum at the level of the caudate nuclei. There are bilateral, linear cavitated foci of necrosis within the caudate nuclei adjacent to the internal capsule;
bar=5mm. (D) Brain, dog. Photomicrograph at the same level as (C). Bilateral, linear, cavitated foci of necrosis are present adjacent to the internal capsule. H&E
stain; Subgross Image, bar= 1.5mm.
FIGURE 2 | (A) Transverse T2-weighed turbo spin echo MR image at the level of the cerebellar nuclei. There are subtle, bilaterally symmetric hyperintensities of the
cerebellar nuclei (white arrow) that correspond to areas of vacuolation on histopathology. (B) Brain, dog. Subgross photomicrograph of the cerebellum and medulla.
Multifocal regions of pallor are present at the level of the lateral, interposital, and fastigial nuclei (white arrows), corresponding with the MRI. H&E stain. (C) Brain, dog.
High magnification photomicrograph of the cerebellum within a pale region denoted by the arrows in (B). Note the myelin vacuolation (white arrows) and axonal
swelling (spheroid, black arrow). There are increased numbers of glial cells in this region, including microglia and astroglia, which are multifocally undergoing
cytoplasmic swelling. H&E stain; 400magnification; bar= 20m.
muscles multifocally contained small, discrete, well demarcated,
circular, and coalescing vacuoles that were morphologically con-
sistent with lipid. In the kidneys, vacuoles within proximal and
distal tubules were well demarcated, discrete, and circular, con-
sistent with lipidosis. Diffusely throughout hepatic lobules, but
more prominently in periportal regions, hepatocytes contained
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multiple, round, and discrete vacuoles, which did not displace the
nucleus (microvesicular lipidosis).
Fresh and fixed biopsies of the left adductor, triceps brachii,
vastus lateralis, and obliquus capitis cranialis muscles were sub-
mitted under refrigeration to the Comparative Neuromuscular
Laboratory at the University of California San Diego. The unfixed
samples were evaluated in frozen sections and the fixed sam-
ples were evaluated in paraffin. A standard panel of histological
and histochemical stains and reactions were employed includ-
ing hematoxylin and eosin, modified Gomori trichome, periodic
acid-Schiff, myofibrillar adenosine triphosphatase reactions at pH
9.8 and 4.3, esterase, reduced nicotinamide adenine dinucleotide-
tetrazolium reductase, alkaline phosphatase, acid phosphatase,
oil red O, and Staphylococcal protein A-horseradish peroxidase.
The most striking abnormality was the presence of numerous
vacuoles within most myofibers containing excessive and variably
sized intramyofiber lipid droplets utilizing the oil red O stain for
neutral triglycerides (Figure 3). Findings were consistent with
a lipid storage myopathy associated with a fatty acid oxidation
defect (FAOD) or a primary or secondary disorder of carnitine
metabolism.
Quantitative urine organic acids screening was performed in
the Biochemical Genetics Laboratory at the University of Califor-
nia San Diego using gas chromatography-mass spectrometry, as
previously described (3). Testing revealedmoderate urinary excre-
tion of malonic acid (41mmol/mol creatinine; reference inter-
val, 0–1mmol/mol creatinine), lactic acid (256mmol/mol creati-
nine; reference interval, 0–200mmol/mol creatinine), the ketones
3OH  butyric acid (1109mmol/mol creatinine; reference inter-
val, 0–11mmol/mol creatinine), acetoacetic acid (275mmol/mol
creatinine; reference interval, 0–1mmol/mol creatinine), suberic
FIGURE 3 | Photomicrograph of cryosections of the triceps muscle
stained with oil red O stain reveals the presence of numerous
intramyofiber lipid droplets, consistent with a lipid storage myopathy.
Oil red O stain; bar= 50m.
acid (30mmol/mol creatinine; reference interval, 0–4mmol/mol
creatinine), and hexanoylglycine (10mmol/mol creatinine; refer-
ence interval, <2mmol/mol creatinine). This pattern of abnor-
malities suggested a FAOD such as medium-chain acyl-CoA
dehydrogenase deficiency (MCADD) (4, 5).
For further investigation, plasma acylcarnitine analysis was
performed and revealed elevated C14:1 (0.26M; reference inter-
val, 0–0.2M) with an elevated C14:C8:1 ratio (14.51; refer-
ence interval, <1.25), an elevated C16:1 (0.21M; reference
interval, 0–0.07M) with an elevated C16/C8.1 ratio (16.61;
reference interval <1.7) and elevated C18.1 (0.41M; refer-
ence interval, 0–0.24M) with an elevated C18.1/C8.1 ratio
(23.17 reference interval >1.7) (6). These compounds are rep-
resentative of long-chain fatty acids (LCFAs) 14–18 carbons in
length. This pattern suggests a long-chain FAOD such as very
long-chain acyl-CoA dehydrogenase deficiency (VLCADD) or
carnitine palmitoyltransferase-2 (CPT2) deficiency. The C3DC
(malonyl)-carnitine was not elevated, ruling out a primary mal-
onic aciduria (5, 7).
BACKGROUND
Organic acidurias (OAs) and mitochondrial FAODs are inborn
errors of metabolism that have been described rarely in the veteri-
nary literature. OAs involve defects in the metabolic pathways of
carbohydrates, proteins, or fats. For example, -2 hydroxyglutaric
aciduria, one of the most well described OAs in the veterinary lit-
erature, involves a defect in the enzyme that converts -2 hydrox-
yglutarate into 2-oxoglutarate, a citric acid cycle intermediate
and glutamate metabolite (8). In addition, there have been single
reports of malonic aciduria in a family of Maltese dogs (9) and
a combined malonic and methylmalonic aciduria in a Labrador
retriever (10). Mitochondrial FAODs, more specifically, involve
a deficiency of one or more enzymes involved in the transport
and -oxidation of fatty acids, decreasing the ability of cells to
use fat for energy production and leading to the accumulation of
substrates upstream from the defect. These include deficiencies in
CPTs (involved in the uptake of fatty acids by the mitochondria)
and in acyl-CoA dehydrogenases (involved in the -oxidation of
fatty acids) (11). Veterinary reports include that of a dog with
refractory seizures secondary to MCADD (12) and a report of
two horses with rhabdomyolysis secondary to multiple acyl-CoA
dehydrogenase deficiency (MADD) (13).
DISCUSSION
Metabolic profiling in the patient described in this report was
consistent with a FAOD. FAO, or more specifically -oxidation,
occurs in the mitochondria and involves the breakdown of fatty
acids into acetyl-CoA. Acetyl-CoA then acts as the primary sub-
strate for the citric acid cycle, which produces ATP and the reduc-
ing coenzymes (e.g., NADH and FADH2) used in the electron
transport chain (i.e., oxidative phosphorylation) for further ATP
production. Acetyl-CoA can be formed from the breakdown of
fats, glucose (via glycolysis), ketones, and proteins. In order for -
oxidation to occur, fatty acids must first enter the mitochondria
(Figure 4). The ability of fatty acids to cross the mitochondrial
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FIGURE 4 | Generalized schematic depicting mitochondrial FAO. Fatty acids enter the mitochondria with MCFAs and SCFAs diffusing in and LCFAs requiring
the assistance of a number of molecules including acyl-CoA synthase, CPT1, carnitine, acylcarnitine translocase, and CPT2 to enter the mitochondria. This process
is inhibited by malonyl-CoA, which inhibits CPT1. Malonyl-CoA is primarily formed from acetyl-CoA in a reaction catalyzed by acetyl-CoA carboxylase (ACC).
Malonyl-CoA can be metabolized back into acetyl-CoA by MCD. The roles of malonyl-CoA include the synthesis and elongation of fatty acids in reactions catalyzed
by fatty acid synthase (FAS), and the inhibition of CPT1. Once within the mitochondria, fatty acids undergo -oxidation to form acetyl-CoA. VLCAD oxidizes LCFAs,
MCAD oxidizes MCFAs, and short-chain acyl-CoA dehydrogenase (SCAD) oxidizes SCFA. Acetyl-CoA is then shuttled into the citric acid cycle for production of ATP
and reducing coenzymes, such as NADH and FADH2. These reducing coenzymes can then be utilized in oxidative phosphorylation to produce additional ATP.
membranes depends on the number of carbons in the chain.
Medium-chain fatty acids (MCFAs) and short-chain fatty acids
(SCFAs) are able to diffuse into the mitochondria without the
use of a carrier molecule. LCFAs require the use of the transport
molecules CPT1, CPT2, and acylcarnitine translocase in a step-
wise process utilizing carnitine. -oxidation involves the stepwise
removal of two carbons at a time from the fatty acids to form
molecules of acetyl-CoA. Each of these reactions is catalyzed by
enzymes specific to the length of the molecule. For example, very
long-chain acyl-CoA dehydrogenase will shorten very long-chain
fatty acids (VLCFAs) and LCFAs intoMCFAs, releasingmolecules
of acetyl-CoA in the process. Medium-chain acyl-CoA dehydro-
genase, in turn, will shorten MCFAs into SCFAs in a process that
also releases acetyl-CoA. A defect at any level in this process may
lead to an impaired ability to utilize energy from fats (11, 14, 15).
In addition to entering the citric acid cycle, acetyl-CoA also
stimulates gluconeogenesis and is used in the formation of ketones
and malonyl-CoA (14, 15). Malonyl-CoA plays two major roles
in the fed state in order to promote fat storage over -oxidation.
In a series of reactions catalyzed by the fatty acid synthase com-
plex, it is used to form LCFAs, and eventually triglycerides, in
adipogenic tissue (e.g., liver and adipocytes) (16). In addition,
it inhibits CPT1, preventing the transport of LCFAs across the
mitochondrial membrane, which is the rate-limiting step in -
oxidation of LCFAs (17). During times of energy need, malonyl-
CoA levels are decreased by malonyl-CoA decarboxylase (MCD),
which metabolizes malonyl-CoA into acetyl-CoA and carbon
dioxide, decreasing its inhibition of -oxidation (16).
Fatty acid oxidation defects are poorly recognized and classified
in the veterinary literature, and the specific enzymatic defect was
not identified in this case. Enzymatic assays in cultured fibrob-
lasts and gene sequencing would have been useful in definitive
identification of the affected enzymes, and are widely utilized
in people. While the elevated levels and proportions of long-
chain acylcarnitines weremost supportive of a VLCADDor CPT2
deficiency, the organic acid screen revealed a hexanoylglycinuria,
which has been most frequently associated with MCADD and
MADD (4, 5, 11). Amoderatemalonic aciduria was also identified
on the urine organic acid screen, which, to the authors’ knowledge,
has not been previously associated with a FAOD. Canine malonic
aciduria has been described in a family of Maltese dogs with neu-
rological signs (9), and in a Labrador retriever that also suffered
from methylmalonic aciduria (10). As an acylcarnitine analysis
was not performed in the report of Maltese dogs, it is unclear
whether these dogs suffered from a primary malonic aciduria or
some other inborn error of metabolism with a secondary malonic
aciduria, as suspected in this patient. Primary malonic aciduria
has been well characterized in the human literature and is most
commonly associated with a deficiency of MCD, the enzyme
that metabolizes malonyl-CoA. This diagnosis is confirmed by
identifying elevated malonylcarnitine levels, reduced MCD lev-
els in cultured fibroblasts, and genetic testing (5, 16, 17). This
defect was considered unlikely in the patient of this report due to
the normal malonylcarnitine levels. Clinical signs and laboratory
abnormalities associated with malonic aciduria are very similar to
those seen in this patient and overlap substantially with many of
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the FAODs (5, 9, 10, 16–18). This is likely due to the inhibitory
effect that elevated levels of malonyl-CoA have on -oxidation of
fatty acids. Therapeutic strategies are also similar.
The phenotypes of OAs and FAODs are heterogenous and
overlap substantially. Clinical signs and laboratory abnormalities
are often episodic and may be induced by stressors such as fasting
and infection (5, 11, 19, 20). The dog in this report had peri-
ods of hypoglycemia, hyperlactemia, and ketonuria, and clinical
signs worsened with fasting, consistent with various OAs and
FAODs described in the human literature. The hypoglycemia and
hyperlactemia can be explained by an increased reliance upon
glycolysis due to decreased availability of ATP from FAO, a lack
of induction of gluconeogenesis by the products of -oxidation,
and on inhibition of enzymes by accumulated metabolites. While
human FAODs are classically associated with a hypoketotic hypo-
glycemia, ketone levels may be variable in both pure FAODs and
in FAODs that occur with other concurrent metabolic abnormal-
ities (e.g., mitochondrial disorders) (5, 11, 15, 20). Ketogenesis
requires initial -oxidation, which was defective in this patient.
The presence of ketones in this patient was likely due to the fact
that the block in -oxidation was incomplete and that dysfunction
of -oxidation can result in outflow of acetyl-CoA (the major
substrate in ketogenesis) from other sources, such as ketogenic
amino acids (14).
Reported clinical signs in the human and veterinary liter-
ature include encephalopathies, developmental delay, seizures,
myopathic syndromes (including lipid storage myopathies and
rhabdomyolysis), cardiomyopathies, hepatopathies, and sudden
neonatal death (5, 11, 15, 19, 20). The major clinical signs of
the dog in this report were initially episodic and were reflec-
tive of a bilaterally symmetric encephalopathy. The exact cause
of intracranial changes in FAODs and OAs is unknown, but
neonatal hypoglycemia, metabolic crises, lactic acidemia, disor-
dered energy production, and direct toxic effects of accumulated
metabolites have been proposed as potential mechanisms (20, 21).
Brain MRI abnormalities described in the human literature are
also heterogenous and dependent on the specific syndrome, the
severity of signs, and the age of the affected individual. Abnor-
malities may include white matter changes, gray matter changes,
atrophy, and/or evidence of neuronal migration defects (21, 22).
Bilaterally symmetric basal ganglia lesions, as predominated in the
dog in the case reported here, have been found in many of the
inborn errors ofmetabolism affecting the brain, including FAODs,
likely secondary to the highly metabolically active nature of these
nuclei (21–23). A retrospective study examining MRI abnor-
malities after hypoglycemic crises in infants and children with
inborn errors of metabolism, including FAODs, correlated basal
ganglia lesions with hypoglycemia during the ages 6–22months
(23). Lesions of the caudate nuclei have been described in
other metabolic disorders of dogs including -2-hydroxyglutaric
aciduria, GM2-gangliosidosis, and Alaskan Husky encephalopa-
thy, as well as in a dog with recurrent hypoglycemia secondary to
an insulinoma (8, 22–26).
On post-mortem examination, the dog described here had
significant changes in a variety of organs. Lipid accumulation
was identified in the liver, kidneys, and muscles. Lipid stor-
age myopathy has been described in FAODs and disorders of
carnitine metabolism and is likely secondary to an inability of
the cells to properly metabolize fats (27). Urine organic acid
analysis in a series of dogs with lipid storage myopathy supported
an etiology of disorders of mitochondrial oxidative metabolism
(28). In addition, the horses with MADD were found to have
microvesicular lipidosis on muscle biopsy in addition to signs of
rhabdomyolysis (13).
The mainstays of treatment for FAODs are provision of a low-
fat, high-carbohydrate diet, as well as defect-specific fatty acid
restriction/supplementation (e.g., restricting LCFAs and supple-
menting MCFAs in VLCADD) and carnitine and/or riboflavin
supplementation. There are reports of improvement in urinary
organic acid excretion, acylcarnitine levels, clinical signs, and the
frequency of metabolic crises with therapy (11, 15, 20). A low-fat
diet high in MCFAs was successful in treatment of the Maltese
dogs with malonic aciduria (9). This therapy was not attempted
in the patient described here due to the post-mortem nature of
the diagnosis.
CONCLUDING REMARKS
This paper describes the clinical, MRI, and histopathological
abnormalities associated with a FAOD in a dog. Abnormalities
included episodic hypoglycemia with at least a single instance
of ketonuria, intermittent lactic acidosis, episodic neurological
deficits progressing to persistent severe deficits, a bilaterally
symmetrical multifocal necrotizing encephalopathy, multi-organ
lipid accumulation (kidneys, liver, and muscle), and exacerbation
by stressors including fasting. Metabolic screening, and muscle
biopsy examination for lipid storage myopathy, should be per-
formed in young dogs presenting with episodic multifocal and
symmetrical encephalopathies since inborn errors of metabolism,
such as FAODs and OAs, may be amenable to dietary therapeutic
interventions. Enzymatic activity assays in cultured skin fibrob-
lasts and gene sequencing are available and may be useful in
identifying the specific enzymatic defect in future patients.
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